Tango Therapeutics (TNGX) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to -$152.8 million.
- Tango Therapeutics' Enterprise Value rose 4789.55% to -$152.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$152.8 million, marking a year-over-year increase of 4789.55%. This contributed to the annual value of -$257.9 million for FY2024, which is 2421.07% up from last year.
- Per Tango Therapeutics' latest filing, its Enterprise Value stood at -$152.8 million for Q3 2025, which was up 4789.55% from -$180.8 million recorded in Q2 2025.
- Tango Therapeutics' 5-year Enterprise Value high stood at -$53.2 million for Q2 2021, and its period low was -$506.1 million during Q3 2021.
- Its 5-year average for Enterprise Value is -$308.6 million, with a median of -$333.6 million in 2023.
- Per our database at Business Quant, Tango Therapeutics' Enterprise Value tumbled by 21268357.94% in 2021 and then surged by 4789.55% in 2025.
- Over the past 5 years, Tango Therapeutics' Enterprise Value (Quarter) stood at -$487.5 million in 2021, then grew by 24.9% to -$366.1 million in 2022, then rose by 7.05% to -$340.3 million in 2023, then rose by 24.21% to -$257.9 million in 2024, then surged by 40.75% to -$152.8 million in 2025.
- Its Enterprise Value was -$152.8 million in Q3 2025, compared to -$180.8 million in Q2 2025 and -$216.7 million in Q1 2025.